Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the…

Posted: June 13, 2022 at 2:35 am

SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the rationale and plans for its upcoming Phase 3 ZILO-301 (zilovertamab plus ibrutinib targeting ROR1 for patients with Mantle Cell Lymphoma) clinical trial will be highlighted in a poster presentation at the European Hematology Association (EHA) 2022 Hybrid Congress. ZILO-301 is designed to evaluate the efficacy and safety of zilovertamab, an investigational anti-ROR1 monoclonal antibody, plus ibrutinib compared to ibrutinib monotherapy for the treatment of patients with relapsed or refractory mantle cell lymphoma (R/R MCL).

Originally posted here:
Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the...

Related Posts